Patients may find that their usual morning meal feels too heavy or triggers discomfort
Eli Lilly reported these results in mid-2025, and the retatrutide availability timeline now points toward potential FDA approval no earlier than 2027, as additional phase 3 trials continue
Injections are placed into the subcutaneous fat layer not into muscle, and not so superficially that the product sits in the dermis, which increases the risk of surface irregularity
non-supplemented baseline Before: 145 lbs, 28% body fat, active trainer, strong metabolic baseline Protocol: 300 kcal deficit, 1.8g protein/kg, 2g L-carnitine daily, 4 resistance + 3 cardio sessions weekly After: 135 lbs, 22% body fat (10 lbs loss, ~9 lbs fat + 1 lb muscle), visible abdominal and shoulder definition Result: L-carnitine + training allowed aggressive deficit while preserving strength